{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:17:36Z","timestamp":1783387056772,"version":"3.54.6"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23H02985"],"award-info":[{"award-number":["23H02985"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K08117"],"award-info":[{"award-number":["23K08117"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Purpose<\/jats:title>\n                    <jats:p>The peritoneal cavity constitutes a unique immune microenvironment that critically influences the pathobiology of peritoneal metastasis (PM). This study aimed to clarify the mechanisms by which local immune alterations affect the efficacy of intraperitoneal (IP) chemotherapy for PM from gastric cancer (GC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Peritoneal lavage or ascitic fluid was obtained from 42 patients with GC and PM treated with IP paclitaxel (PTX) in combination with systemic oxaliplatin and oral S-1. Serial samples from 31 patients were analyzed after 1\u20133 cycles of chemotherapy. Immune cell subsets were evaluated using multicolor flow cytometry with monoclonal antibodies, and the functional properties of peritoneal eosinophils were assessed using gene expression profiling and cytotoxicity assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IP chemotherapy was associated with decreased CD4(+) T cells and increased CD11b(+) myeloid cells. Notably, many patients, particularly those with negative cytology (CY0), exhibited striking recruitment of CD66b(+) CD16(\u2013) CD193(+) Siglec-F(+) eosinophils into the peritoneal cavity. Eosinophil expansion was correlated with improved clinical outcomes. Post-treatment eosinophils displayed an activated, partially degranulated phenotype with elevated CD11b and CD63 expression and distinct messenger RNA signatures compared with circulating eosinophils. Peritoneal eosinophils demonstrated the ability to induce apoptosis in GC cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IP PTX promotes the recruitment and activation of eosinophils with potent antitumor activity in the peritoneal cavity. Early post-treatment abdominal eosinophilia is a robust prognostic biomarker and may represent a promising therapeutic target to enhance the efficacy of IP chemotherapy in patients with PM from GC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-19075-x","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:56:15Z","timestamp":1769702175000},"page":"5283-5292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Intraperitoneal Paclitaxel-Induced Eosinophil Recruitment as a Potential Mediator of Tumor Response in Peritoneal Metastases from Gastric Cancer"],"prefix":"10.1245","volume":"33","author":[{"given":"Misaki","family":"Matsumiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroharu","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kurashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Ohzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyo","family":"Miyato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Sata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Kitayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"3","key":"19075_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"19075_CR2","doi-asserted-by":"crossref","unstructured":"Manzanedo I, Pereira F, Cascales-Campos P, et al. Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP). J Clin Med. 2023;12(11).","DOI":"10.3390\/jcm12113774"},{"issue":"6","key":"19075_CR3","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/ijc.34780","volume":"154","author":"A Rijken","year":"2024","unstructured":"Rijken A, Pape M, Simkens GA, et al. Peritoneal metastases from gastric cancer in a nationwide cohort: Incidence, treatment and survival. Int J Cancer. 2024;154(6):992\u20131002.","journal-title":"Int J Cancer."},{"key":"19075_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53\u201363.","journal-title":"Cancer Treat Res."},{"issue":"9","key":"19075_CR5","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol. 1992;10(9):1485\u201391.","journal-title":"J Clin Oncol."},{"issue":"1","key":"19075_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1349-7006.2010.01747.x","volume":"102","author":"T Kamei","year":"2011","unstructured":"Kamei T, Kitayama J, Yamaguchi H, et al. Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules. Cancer sci. 2011;102(1):200\u20135.","journal-title":"Cancer sci"},{"issue":"2","key":"19075_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ags3.12060","volume":"2","author":"J Kitayama","year":"2018","unstructured":"Kitayama J, Ishigami H, Yamaguchi H, et al. Treatment of patients with peritoneal metastases from gastric cancer. Ann Gastroenterol Surg. 2018;2(2):116\u201323.","journal-title":"Ann Gastroenterol Surg"},{"key":"19075_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.864647","volume":"12","author":"A Prabhu","year":"2022","unstructured":"Prabhu A, Mishra D, Brandl A, Yonemura Y. Gastric cancer with peritoneal metastasis-a comprehensive review of current intraperitoneal treatment modalities. Front Oncol. 2022;12:864647.","journal-title":"Front Oncol."},{"issue":"4","key":"19075_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450\u201361.","journal-title":"Cancer Cell."},{"issue":"6382","key":"19075_CR10","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science."},{"issue":"5","key":"19075_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350.","journal-title":"Nat Med"},{"issue":"3","key":"19075_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"issue":"7","key":"19075_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022141","volume":"6","author":"A Cassado Ados","year":"2011","unstructured":"Cassado Ados A, de Albuquerque JA, Sardinha LR, et al. Cellular renewal and improvement of local cell effector activity in peritoneal cavity in response to infectious stimuli. PloS One. 2011;6(7):e22141.","journal-title":"PloS One"},{"issue":"4","key":"19075_CR14","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/JLB.5MIR0720-271RR","volume":"109","author":"M Liu","year":"2021","unstructured":"Liu M, Silva-Sanchez A, Randall TD, Meza-Perez S. Specialized immune responses in the peritoneal cavity and omentum. J Leukoc Biol. 2021;109(4):717\u201329.","journal-title":"J Leukoc Biol"},{"key":"19075_CR15","first-page":"123","volume":"434","author":"Y Okabe","year":"2021","unstructured":"Okabe Y. Immune niche within the peritoneal cavity. Curr Top Microbiol Immunol. 2021;434:123\u201334.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"7","key":"19075_CR16","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1245\/s10434-020-09388-4","volume":"28","author":"S Saito","year":"2021","unstructured":"Saito S, Yamaguchi H, Ohzawa H, et al. Intraperitoneal administration of paclitaxel combined with S-1 plus oxaliplatin as induction therapy for patients with advanced gastric cancer with peritoneal metastases. Ann Surg Oncol. 2021;28(7):3863\u201370.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"19075_CR17","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/cyto.b.21978","volume":"100","author":"K Takahashi","year":"2021","unstructured":"Takahashi K, Kurashina K, Saito S, et al. Flow cytometry-based analysis of tumor-leukocyte ratios in peritoneal fluid from patients with advanced gastric cancer. Cytometry B Clin Cytom. 2021;100(6):666\u201375.","journal-title":"Cytometry B Clin Cytom"},{"issue":"6","key":"19075_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1317420","volume":"6","author":"V Lucarini","year":"2017","unstructured":"Lucarini V, Ziccheddu G, Macchia I, et al. IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. Oncoimmunology. 2017;6(6):e1317420.","journal-title":"Oncoimmunology"},{"issue":"5069","key":"19075_CR19","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1126\/science.1636093","volume":"257","author":"RI Tepper","year":"1992","unstructured":"Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science. 1992;257(5069):548\u201351.","journal-title":"Science"},{"issue":"3","key":"19075_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1084\/jem.20021683","volume":"197","author":"J Mattes","year":"2003","unstructured":"Mattes J, Hulett M, Xie W, et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med. 2003;197(3):387\u201393.","journal-title":"J Exp Med"},{"issue":"7","key":"19075_CR21","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.4049\/jimmunol.178.7.4222","volume":"178","author":"L Simson","year":"2007","unstructured":"Simson L, Ellyard JI, Dent LA, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol. 2007;178(7):4222\u20139.","journal-title":"J Immunol"},{"issue":"8","key":"19075_CR22","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.4049\/jimmunol.0900504","volume":"183","author":"R Lotfi","year":"2009","unstructured":"Lotfi R, Herzog GI, DeMarco RA, et al. Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells. J Immunol. 2009;183(8):5023\u201331.","journal-title":"J Immunol"},{"issue":"Suppl","key":"19075_CR23","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.alit.2015.04.009","volume":"64","author":"T Kobayashi","year":"2015","unstructured":"Kobayashi T, Soma T, Noguchi T, et al. ATP drives eosinophil effector responses through P2 purinergic receptors. Allergol Int. 2015;64(Suppl):S30-36.","journal-title":"Allergol Int"},{"issue":"1","key":"19075_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1515058","volume":"8","author":"A Perales-Puchalt","year":"2019","unstructured":"Perales-Puchalt A, Svoronos N, Villarreal DO, et al. IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment. Oncoimmunology. 2019;8(1):e1515058.","journal-title":"Oncoimmunology"},{"issue":"8","key":"19075_CR25","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1158\/2326-6066.CIR-19-0616","volume":"8","author":"TS Lau","year":"2020","unstructured":"Lau TS, Chan LKY, Man GCW, et al. Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4\/IKK2\/SNARE-dependent exocytosis. Cancer Immunol Res. 2020;8(8):1099\u2013111.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"19075_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/2326-6066.CIR-13-0196","volume":"2","author":"BP Davis","year":"2014","unstructured":"Davis BP, Rothenberg ME. Eosinophils and cancer. Cancer Immunol Res. 2014;2(1):1\u20138.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"19075_CR27","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41568-020-0283-9","volume":"20","author":"S Grisaru-Tal","year":"2020","unstructured":"Grisaru-Tal S, Itan M, Klion AD, Munitz A. A new dawn for eosinophils in the tumour microenvironment. Nat Rev Cancer. 2020;20(10):594\u2013607.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"19075_CR28","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1002\/1097-0142(19860915)58:6<1321::AID-CNCR2820580623>3.0.CO;2-O","volume":"58","author":"K Iwasaki","year":"1986","unstructured":"Iwasaki K, Torisu M, Fujimura T. Malignant tumor and eosinophils. I. Prognostic significance in gastric cancer. Cancer. 1986;58(6):1321\u20137.","journal-title":"Cancer"},{"issue":"5","key":"19075_CR29","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/sj.bjc.6600161","volume":"86","author":"A Cuschieri","year":"2002","unstructured":"Cuschieri A, Talbot IC, Weeden S, Party MRCUGCW. Influence of pathological tumour variables on long-term survival in resectable gastric cancer. Br J Cancer. 2002;86(5):674\u20139.","journal-title":"Br J Cancer"},{"issue":"11","key":"19075_CR30","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/bjc.1996.630","volume":"74","author":"I Songun","year":"1996","unstructured":"Songun I, van de Velde CJ, Hermans J, et al. Expression of oncoproteins and the amount of eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer. Dutch Gastric Cancer Group (DGCG). Br J Cancer. 1996;74(11):1783\u20138.","journal-title":"Br J Cancer"},{"issue":"3","key":"19075_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/00130404-200505000-00008","volume":"11","author":"SJ Alrawi","year":"2005","unstructured":"Alrawi SJ, Tan D, Stoler DL, et al. Tissue eosinophilic infiltration: a useful marker for assessing stromal invasion, survival and locoregional recurrence in head and neck squamous neoplasia. Cancer J. 2005;11(3):217\u201325.","journal-title":"Cancer J"},{"issue":"9","key":"19075_CR32","volume":"10","author":"H Popov","year":"2018","unstructured":"Popov H, Donev IS, Ghenev P. Quantitative analysis of tumor-associated tissue eosinophilia in recurring bladder cancer. Cureus. 2018;10(9):e3279.","journal-title":"Cureus"},{"issue":"5","key":"19075_CR33","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00262-018-2255-4","volume":"68","author":"SCS Simon","year":"2019","unstructured":"Simon SCS, Utikal J, Umansky V. Opposing roles of eosinophils in cancer. Cancer Immunol Immunother. 2019;68(5):823\u201333.","journal-title":"Cancer Immunol Immunother"},{"issue":"2\u20134","key":"19075_CR34","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1159\/000024154","volume":"118","author":"H Kubo","year":"1999","unstructured":"Kubo H, Loegering DA, Adolphson CR, Gleich GJ. Cytotoxic properties of eosinophil granule major basic protein for tumor cells. Int Arch Allergy Immunol. 1999;118(2\u20134):426\u20138.","journal-title":"Int Arch Allergy Immunol"},{"issue":"12","key":"19075_CR35","doi-asserted-by":"publisher","first-page":"7443","DOI":"10.4049\/jimmunol.1000446","volume":"185","author":"F Legrand","year":"2010","unstructured":"Legrand F, Driss V, Delbeke M, et al. Human eosinophils exert TNF-alpha and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J Immunol. 2010;185(12):7443\u201351.","journal-title":"J Immunol"},{"issue":"6","key":"19075_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/PL00006690","volume":"50","author":"DJ Costain","year":"2001","unstructured":"Costain DJ, Guha AK, Liwski RS, Lee TD. Murine hypodense eosinophils induce tumour cell apoptosis by a granzyme B-dependent mechanism. Cancer Immunol Immunother. 2001;50(6):293\u20139.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"19075_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13046-024-03129-1","volume":"43","author":"AR Gambardella","year":"2024","unstructured":"Gambardella AR, Antonucci C, Zanetti C, et al. IL-33 stimulates the anticancer activities of eosinophils through extracellular vesicle-driven reprogramming of tumor cells. J Exp Clin Cancer Res. 2024;43(1):209.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"19075_CR38","doi-asserted-by":"publisher","first-page":"1776059","DOI":"10.1080\/2162402X.2020.1776059","volume":"9","author":"M Kienzl","year":"2020","unstructured":"Kienzl M, Hasenoehrl C, Valadez-Cosmes P, et al. IL-33 reduces tumor growth in models of colorectal cancer with the help of eosinophils. Oncoimmunology. 2020;9(1):1776059.","journal-title":"Oncoimmunology"},{"key":"19075_CR39","doi-asserted-by":"crossref","unstructured":"Andreone S, Spadaro F, Buccione C, et al. IL-33 promotes CD11b\/CD18-mediated adhesion of eosinophils to cancer cells and synapse-polarized degranulation leading to tumor cell killing. Cancers (Basel). 2019;11(11).","DOI":"10.3390\/cancers11111664"},{"issue":"6","key":"19075_CR40","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/ni.3159","volume":"16","author":"R Carretero","year":"2015","unstructured":"Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hammerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015;16(6):609\u201317.","journal-title":"Nat Immunol"},{"issue":"21","key":"19075_CR41","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1158\/0008-5472.CAN-21-0839","volume":"81","author":"S Grisaru-Tal","year":"2021","unstructured":"Grisaru-Tal S, Dulberg S, Beck L, et al. Metastasis-entrained eosinophils enhance lymphocyte-mediated antitumor immunity. Cancer Res. 2021;81(21):5555\u201371.","journal-title":"Cancer Res"},{"issue":"6","key":"19075_CR42","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/sji.12554","volume":"85","author":"SM O\u2019Flaherty","year":"2017","unstructured":"O\u2019Flaherty SM, Sutummaporn K, Haggtoft WL, et al. TLR-stimulated eosinophils mediate recruitment and activation of NK cells in vivo. Scand J Immunol. 2017;85(6):417\u201324.","journal-title":"Scand J Immunol"},{"issue":"3","key":"19075_CR43","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1189\/jlb.0607366","volume":"83","author":"R Lotfi","year":"2008","unstructured":"Lotfi R, Lotze MT. Eosinophils induce DC maturation, regulating immunity. J Leukoc Biol. 2008;83(3):456\u201360.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"19075_CR44","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2303.2004.00132.x","volume":"15","author":"TK Kobayashi","year":"2004","unstructured":"Kobayashi TK, Muramatsu M, Ueda M, et al. Eosinophilic ascites: taxol-induced hypersensitivity? Cytopathology. 2004;15(3):171\u20132.","journal-title":"Cytopathology"},{"issue":"8966","key":"19075_CR45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0140-6736(95)92654-2","volume":"346","author":"MW Saville","year":"1995","unstructured":"Saville MW, Lietzau J, Pluda JM, et al. Treatment of HIV-associated Kaposi\u2019s sarcoma with paclitaxel. Lancet. 1995;346(8966):26\u20138.","journal-title":"Lancet"},{"issue":"3","key":"19075_CR46","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.1998.16.3.1112","volume":"16","author":"L Welles","year":"1998","unstructured":"Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi\u2019s sarcoma. J Clin Oncol. 1998;16(3):1112\u201321.","journal-title":"J Clin Oncol"},{"issue":"24","key":"19075_CR47","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","volume":"21","author":"C Gebhardt","year":"2015","unstructured":"Gebhardt C, Sevko A, Jiang H, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with Ipilimumab. Clin Cancer Res. 2015;21(24):5453\u20139.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"19075_CR48","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","volume":"22","author":"A Martens","year":"2016","unstructured":"Martens A, Wistuba-Hamprecht K, Geukes Foppen M, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with Ipilimumab. Clin Cancer Res. 2016;22(12):2908\u201318.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"19075_CR49","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"B Weide","year":"2016","unstructured":"Weide B, Martens A, Hassel JC, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016;22(22):5487\u201396.","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-19075-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-19075-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-19075-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T06:02:28Z","timestamp":1778911348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-19075-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["19075"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-19075-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"This study was reviewed and approved by the institutional review board, Jichi Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}